HeartSciences, a cutting-edge medical technology company, recently unveiled groundbreaking research in Cardiovascular Diabetology on March 12, 2024. Their study delved into the effectiveness of the innovative MyoVista® technology in identifying asymptomatic left ventricular dysfunction in individuals with Type 2 Diabetes.
The study pitted an advanced AI-ECG model utilizing MyoVista® wavECG™ features against traditional methods such as NT-proBNP and the ARIC HF risk score for screening asymptomatic left ventricular dysfunction in Type 2 Diabetes patients. The findings revealed that the MyoVista® wavECG™ model outperformed NT-proBNP and the ARIC HF risk score, showcasing superior accuracy in detecting asymptomatic left ventricular dysfunction among individuals with Type 2 Diabetes.
This research highlights the potential of machine learning models incorporating additional features extracted from MyoVista® wavECG™ for screening asymptomatic left ventricular dysfunction in Type 2 Diabetes patients. It offers a promising alternative approach to screening for heart failure, potentially revolutionizing patient care in the realm of cardiovascular health.
HSCS Stock Shows Stability with Potential for Growth in Pre-Market Trading on March 12, 2024
On March 12, 2024, HSCS stock had a relatively stable performance, with a slight decrease of 0.99% from the previous market close. The stock closed at $0.12, trading in the middle of its 52-week range and below its 200-day simple moving average.
Despite the slight drop in price, there seems to be some positive momentum in pre-market trading, with the stock rising $0.00. This indicates that investors may be showing some interest in the stock and could potentially drive the price higher throughout the trading day.
HSCS Stock Reports Decrease in Net Income and Earnings Per Share – Investors Watching Closely
On March 12, 2024, HSCS stock experienced a slight decrease in its net income compared to the previous year and quarter. The company reported a net income of -$6.35 million over the past year, which represents a 31.61% decrease from the previous year. In the last quarter, HSCS reported a net income of -$1.75 million, reflecting a 27.91% decrease from the previous quarter.
Similarly, the earnings per share (EPS) for HSCS also saw a significant decrease over the past year and quarter. The EPS for the past year was reported at -$0.80, representing a staggering 4389.89% decrease from the previous year. In the last quarter, the EPS was reported at -$0.16, marking a 20.79% decrease from the previous quarter.
Investors and analysts will likely be closely monitoring HSCS stock in the coming days to see if there are any significant changes in the company’s financial performance. It will be crucial for HSCS to address the decline in net income and EPS in order to regain investor confidence and potentially improve its stock performance in the future.
